# Acknowledgments

For the CNV analysis, we thank Ben Voight for kindly providing the CtS list used by the GIANT consortium.

**Discovery cohorts**

**AGES:** This study has been funded by NIH contract N01-AG-1-2100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00-063. The researchers are indebted to the participants for their willingness to participate in the study.

**ARIC :** The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. AK was supported by the Emmy Noether Programme of the German Research Foundation (KO3598/2-1).The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.

**BLSA :** The BLSA was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. A portion of that support was through a R&D contract with MedStar Research Institute.

**Cardiovascular Health Study (CHS) :** This CHS research was supported by NHLBI contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, HHSN268201200036C and NHLBI grants HL080295, HL087652, HL105756 with additional contribution from NINDS. Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the NIA. See also <http://www.chs-nhlbi.org/pi.htm>. DNA handling and genotyping at Cedars-Sinai Medical Center was supported in part by the National Center for Research Resources, grant UL1RR033176, and is now at the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124; in addition to the National Institute of Diabetes and Digestive and Kidney Disease grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

**CoLaus :** The CoLaus authors thank Yolande Barreau, Mathieu Firmann, Vladimir Mayor, Anne-Lise Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy Sagette, Jeanne Ecoffey and Sylvie Mermoud for data collection. The CoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (33CSCO-122661, 3200BO-111361/2, 3100AO-116323/1,310000-112552). The computations for CoLaus imputation were performed in part at the Vital-IT center for high performance computing of the Swiss Institute of Bioinformatics. MB is supported by the Swiss School of Public Health Plus (SSPH+). We thank Vincent Mooser for his contribution to the CoLaus study.

**CROATIA-Korcula :** The CROATIA-Korcula study was funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants to I.R. (108-1080315-0302). We would like to acknowledge the invaluable contributions of the recruitment team in Korcula, the administrative teams in Croatia and Edinburgh and the people of Korcula. The SNP genotyping for the CROATIA-Korcula cohort was performed in Helmholtz Zentrum München, Neuherberg, Germany.

**CROATIA-Split :** The CROATIA-Split study is funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants to I.R. (108-1080315-0302). We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including but not limited to The University of Split and Zagreb Medical Schools and the Croatian Institute for Public Health. The SNP genotyping for the CROATIA-Split cohort was performed by AROS Applied Biotechnology, Aarhus, Denmark.

**CROATIA-Vis :** The CROATIA-Vis study was funded by grants from the Medical Research Council (UK) and Republic of Croatia Ministry of Science, Education and Sports research grants to I.R. (108-1080315-0302). We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including but not limited to The University of Split and Zagreb Medical Schools, the Institute for Anthropological Research in Zagreb and Croatian Institute for Public Health. The SNP genotyping for the CROATIA-Vis cohort was performed in the core genotyping laboratory of the Wellcome Trust Clinical Research Facility at the Western General Hospital, Edinburgh, Scotland.

**Framingham Heart Study :** This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine.   The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center.

**HABC:** This research was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging.

**InCHIANTI :** The InCHIANTI study baseline (1998-2000) was supported as a "targeted project" (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336).

**London Life Sciences Population (LOLIPOP) study:** LOLIPOP EW A: We thank GSK for supporting and genotyping of the data. LOLIPOP EW P : The LOLIPOP study was supported by the British Heart Foundation Grant SP/04/002. LOLIPOP EW610 : The LOLIPOP study was supported by the Wellcome Trust. We thank the participants and research teams involved in LOLIPOP.

**Lothian Birth Cohort 1936** : The LBC1936 research was supported by a programme grant from Research Into Ageing and continues with programme grants from Help the Aged/Research Into Ageing (Disconnected Mind). The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (G0700704/84698). Funding from the Biotechnology and Biological Sciences Research Council (BBSRC), Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC) and Medical Research Council (MRC) is gratefully acknowledged. We thank the LBC1936 participants. We thank Alan Gow, Janie Corley, Caroline Brett, Caroline Cameron, Michelle Taylor, and Alison Pattie for data collection and data entry. We thank the study secretary Paula Davies. We thank the nurses and staff at the Wellcome Trust Clinical Research Facility, where subjects were tested and the genotyping was performed. We thank the staff at the Lothian Health Board. This whole genome association study was funded by the Biotechnology and Biological Sciences Research Council (BBSRC).

**Ogliastra Genetic Park - Talana Study:** We thank the Ogliastra population and all the individuals who participated in this study. We are very grateful to the municipal administrators for their collaboration to the project and for economic and logistic support. This work was supported by grants from the Italian Ministry of Education, University and Research (MIUR) no.5571/DSPAR/2002 and (FIRB) D. M. no. 718/Ric/2005.

**ORCADES :** ORCADES was supported by the Chief Scientist Office of the Scottish Government, the Royal Society, the MRC Human Genetics Unit, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). DNA extractions were performed at the Wellcome Trust Clinical Research Facility in Edinburgh. We would like to acknowledge the invaluable contributions of Lorraine Anderson and the research nurses in Orkney, the administrative team in Edinburgh and the people of Orkney.

**SHIP:** SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network ‘Greifswald Approach to Individualized Medicine (GANI\_MED)’ funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of the ‘Center of Knowledge Interchange’ program of the Siemens AG. The SHIP authors are grateful to Mario Stanke for the opportunity to use his Server Cluster for SNP Imputation.

**The Rotterdam Study :** The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research (NWO); the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Netherlands Heart Foundation; the Ministry of Education, Culture and Science; the Ministry of Health Welfare and Sports; the European Commission; and the Municipality of Rotterdam.   
Support for genotyping was provided by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Consortium for Healthy Aging (NCHA) project nr. 050-060-810. Jacqueline Witteman is supported by NWO grant (vici, 918-76-619). Abbas Dehghan is supported by NOW grant (veni, ) and the EUR Fellowship.

**Replication cohorts**

**Bus Santé study :** This research was conducted in part using data and resources from the Bus Santé study of the Geneva University Hospitals.   This work was partially supported by the Geneva University Hospitals, the Canton of Geneva (Switzerland), the General Directorate of Health (Canton of Geneva), the Swiss School of Public Health Plus (SSPH+) and the Swiss Foundation for Science (Contract No. 33CM30-124087). The investigators of the Bus Santé study thank all the collaborators of the Unit of Population Epidemiology, UNILABS SA (Geneva), and Abbott Diagnostics (Baar, Switzerland). We thank. Dr Olivier GOLAZ, Central laboratory of clinical chemistry, Geneva University Hospitals.

**INGI-Carlantino-Project :** We thank Laura Esposito and Angela D’Eustacchio for technical support. We are very grateful to the municipal administrators for their collaboration on the project and for logistic support. We would like to thank all participants to this study.

**INGI-CILENTO :** We thank the populations of Cilento for their participation in the study. This work was supported by grants from the EU (Vasoplus-037254), the Italian Ministry of Universities (FIRB -RBIN064YAT), the Assessorato Ricerca Regione Campania, the Ente Parco Nazionale del Cilento e Vallo di Diano and the Fondazione Banco di Napoli to MC.

**INGI-FVG-Project :** We thank Laura Esposito and Angela D’Eustacchio for technical support. We are very grateful to the municipal administrators for their collaboration on the project and for logistic support. We would like to thank all participants to this study.

**KORA F3/F4 Studies (Cooperative Health Research in the Region of Augsburg):** The KORA Augsburg studies were financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany and supported by grants from the German Federal Ministry of Education and Research (BMBF). Part of this work was financed by the German National Genome Research Network (NGFN). Our research was supported within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ.

**Ludwigshafen Risk and Cardiovascular Health (LURIC) Study:** LURIC thanks their participants and researchers and acknowledges that it has received funding through the 6th Framework Program (integrated project Bloodomics, grant LSHM-CT-2004-503485) and 7th of Framework Program (integrated project Atheroremo, Grant Agreement number 201668) of the European Union.

**PIVUS :** LL acknowledge funding from the Swedish Research council. AM and APM acknowledge funding from the Wellcome Trust (WT064890, WT081682)

**SHIP-Trend :** SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network ‘Greifswald Approach to Individualized Medicine (GANI\_MED)’ funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of the ‘Center of Knowledge Interchange’ program of the Siemens AG. The SHIP authors are grateful to Mario Stanke for the opportunity to use his Server Cluster for SNP Imputation.

**TwinsUK :** Twins UK (TUK): The study was funded by the Wellcome Trust; European Community’s Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F2-2008-201865-GEFOS and (FP7/2007-2013), ENGAGE project grant agreement HEALTH-F4-2007-201413 and the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254). The study also receives support from the Dept of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London. TDS is an NIHR senior Investigator. The project also received support from a Biotechnology and Biological Sciences Research Council (BBSRC) project grant (G20234). The authors acknowledge the funding and support of the National Eye Institute via an NIH/CIDR genotyping project (PI: Terri Young). NS is supported by the Wellcome Trust (Core Grant Number 091746/Z/10/Z). Genotyping of TwinsUK samples: We thank the staff from the Genotyping Facilities and Variation Informatics at the Wellcome Trust Sanger Institute for sample preparation, Quality Control and Genotyping led by Leena Peltonen and Panos Deloukas; Le Centre National de Génotypage, France, led by Mark Lathrop, for genotyping; Duke University, North Carolina, USA, led by David Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki, led by Aarno Palotie. Genotyping was also performed by CIDR as part of an NEI/NIH project grant.

**The BRItish Genetics of HyperTension (BRIGHT) study:** The BRIGHT study was supported by the Medical Research Council of Great Britain (G9521010D), by the British Heart Foundation (grant number PG/02/128) and The Wellcome Trust as part of the Wellcome Trust Case Control Consortium. The BRIGHT study is extremely grateful to all the patients who participated in the study and the BRIGHT nursing team. We would also like to thank the Barts Genome Centre staff for their assistance with this project. This work forms part of the research themes contributing to the translational research portfolio for Barts and the London Cardiovascular Biomedical Research Unit, which is supported and funded by the National Institute for Health Research.

**Other studies**

**Biobank Japan :** This work was conducted as a part of the BioBank Japan Project that was supported by the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government.

**GEFOS Consortium:** The Genetic Factors for Osteoporosis (GEFOS) consortium was funded by the European Commission (HEALTH-F2-2008-201865-GEFOS).

**London Life Sciences Population (LOLIPOP) study:** We thank the participants and research teams involved in LOLIPOP. LOLIPOP IA P : The LOLIPOP study was supported by the British Heart Foundation Grant SP/04/002. LOLIPOP IA317 : The LOLIPOP study was supported by the British Heart Foundation Grant SP/04/002. LOLIPOP IA610 : The LOLIPOP study was supported by the Wellcome Trust.

**Animal studies**

OB is supported by a Swiss National Foundation grant #PP00P3-133648 and by a bridge grant from the Faculté de Biologie et Médecine de l'Université de Lausanne.

**GEFOS COLLABORATORS**

Karol Estrada1,2,3,139, Unnur Styrkarsdottir4,139, Evangelos Evangelou5,139, Yi-Hsiang Hsu6,7,139, Emma L Duncan8,9,139, Evangelia E Ntzani5,139, Ling Oei1,2,3,139, Omar M E Albagha10, Najaf Amin2, John P Kemp11, Daniel L Koller12, Guo Li13, Ching-Ti Liu14, Ryan L Minster15, Alireza Moayyeri16,17, Liesbeth Vandenput18, Dana Willner8,19, Su-Mei Xiao20,21, Laura M Yerges-Armstrong22, Hou-Feng Zheng23, Nerea Alonso10, Joel Eriksson18, Candace M Kammerer15, Stephen K Kaptoge16, Paul J Leo8, Gudmar Thorleifsson4, Scott G Wilson17,24,25, James F Wilson26,27, Ville Aalto28,29, Markku Alen30, Aaron K Aragaki31, Thor Aspelund32,33, Jacqueline R Center34,35,36, Zoe Dailiana37, David J Duggan38, Melissa Garcia39, Natàlia Garcia-Giralt40, Sylvie Giroux41, Göran Hallmans42, Lynne J Hocking43, Lise Bjerre Husted44, Karen A Jameson45, Rita Khusainova46,47, Ghi Su Kim48, Charles Kooperberg31, Theodora Koromila49, Marcin Kruk50, Marika Laaksonen51, Andrea Z Lacroix31, Seung Hun Lee48, Ping C Leung52, Joshua R Lewis24,25, Laura Masi53, Simona Mencej-Bedrac54, Tuan V Nguyen34,35, Xavier Nogues40, Millan S Patel55, Janez Prezelj56, Lynda M Rose57, Serena Scollen58, Kristin Siggeirsdottir32, Albert V Smith32,33, Olle Svensson59, Stella Trompet60,61, Olivia Trummer62, Natasja M van Schoor63, Jean Woo64, Kun Zhu24,25, Susana Balcells65, Maria Luisa Brandi53, Brendan M Buckley66, Sulin Cheng67,68, Claus Christiansen69, Cyrus Cooper45, George Dedoussis70, Ian Ford71, Morten Frost72,73, David Goltzman74, Jesús González-Macías75,76, Mika Kähönen77,78, Magnus Karlsson79, Elza Khusnutdinova46,47, Jung-Min Koh48, Panagoula Kollia49, Bente Lomholt Langdahl44, William D Leslie80, Paul Lips81,82, Östen Ljunggren83, Roman S Lorenc50, Janja Marc54, Dan Mellström18, Barbara Obermayer-Pietsch62, José M Olmos75,76, Ulrika Pettersson-Kymmer84, David M Reid43, José A Riancho75,76, Paul M Ridker57,85, François Rousseau41,86,87, P Eline Slagboom88,3, Nelson LS Tang89,90, Roser Urreizti65, Wim Van Hul91, Jorma Viikari92,93, María T Zarrabeitia94, Yurii S Aulchenko2, Martha Castano-Betancourt1,2,3, Elin Grundberg95,96,97, Lizbeth Herrera1, Thorvaldur Ingvarsson98,99,33, Hrefna Johannsdottir4, Tony Kwan95,96, Rui Li100, Robert Luben16, Carolina Medina-Gómez1,2, Stefan Th Palsson4, Sjur Reppe101, Jerome I Rotter102, Gunnar Sigurdsson103,33, Joyce B J van Meurs1,2,3, Dominique Verlaan95,96, Frances MK Williams17, Andrew R Wood104, Yanhua Zhou14, Kaare M Gautvik101,105,106, Tomi Pastinen95,96,107, Soumya Raychaudhuri108,109, Jane A Cauley110, Daniel I Chasman57,85, Graeme R Clark8, Steven R Cummings111, Patrick Danoy8, Elaine M Dennison45, Richard Eastell112, John A Eisman34,35,36, Vilmundur Gudnason32,33, Albert Hofman2,3, Rebecca D Jackson113,114, Graeme Jones115, J Wouter Jukema60,116,117, Kay-Tee Khaw16, Terho Lehtimäki118,119, Yongmei Liu120, Mattias Lorentzon18, Eugene McCloskey112,121, Braxton D Mitchell22, Kannabiran Nandakumar6,7, Geoffrey C Nicholson122, Ben A Oostra123, Munro Peacock124, Huibert A P Pols1,2, Richard L Prince24,25, Olli Raitakari28,29, Ian R Reid125, John Robbins126, Philip N Sambrook127, Pak Chung Sham128,129, Alan R Shuldiner 22,130, Frances A Tylavsky131, Cornelia M van Duijn2, Nick J Wareham132, L Adrienne Cupples14,133, Michael J Econs124,12, David M Evans11, Tamara B Harris39, Annie Wai Chee Kung20,21, Bruce M Psaty134,135, Jonathan Reeve136, Timothy D Spector17, Elizabeth A Streeten22,130, M Carola Zillikens1, Unnur Thorsteinsdottir4,33,140, Claes Ohlsson18,140, David Karasik6,7,140, J Brent Richards137,17,140, Matthew A Brown8,140, Kari Stefansson4,33,140, André G Uitterlinden1,2,3,140, Stuart H Ralston10,140, John P A Ioannidis138,5,140, Douglas P Kiel6,7,140, Fernando Rivadeneira1,2,3,140

Affiliations:

1Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.  2Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.  3Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA), Leiden, The Netherlands.  4deCODE Genetics, Reykjavik, Iceland.  5Department of Hygiene and Epidemiology, University of Ioannina, Ioannina, Greece.  6Institute for Aging Research, Hebrew SeniorLife, Boston, USA.  7Department of Medicine, Harvard Medical School, Boston, USA.  8Human Genetics Group, University of Queensland Diamantina Institute, Brisbane, Australia.  9Department of Endocrinology, Royal Brisbane and Women's Hospital, Brisbane, Australia.  10Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.  11Medical Research Council (MRC) Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol, UK.  12Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA.  13Cardiovascular Health Research Unit, University of Washington, Seattle, USA.  14Department of Biostatistics, Boston University School of Public Health, Boston, USA.  15Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA.  16Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.  17Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.  18Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.  19Australian Centre for Ecogenomics, University of Queensland, Brisbane, Australia.  20Department of Medicine, The University of Hong Kong, Hong Kong, China.  21Research Centre of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, Hong Kong, China.  22Department of Medicine, Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD, USA.  23Department of Human Genetics, Lady Davis Institute, McGill University, Montreal, Canada.  24School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.  25Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Perth, Australia.  26Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.  27MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, UK.  28Department of Clinical Physiology, Turku University Hospital, Turku, Finland.  29Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.  30Department of Medical Rehabilitation, Oulu University Hospital and Institute of Health Sciences, Oulu, Finland.  31Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA.  32Icelandic Heart Association, Kopavogur, Iceland.  33Faculty of Medicine, University of Iceland, Reykjavik, Iceland.  34Osteoporosis and Bone Biology Program, Garvan Institute of Medical Research, Sydney, Australia.  35Department of Medicine, University of New South Wales, Sydney, Australia.  36Department of Endocrinology, St Vincents Hospital, Sydney, Australia.  37Department of Orthopaedic Surgery, Medical School University of Thessalia, Larissa, Greece.  38Translational Genomics Research Institute, Phoenix, USA.  39Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, MD, USA.  40Department of Internal Medicine, Hospital del Mar, Instituto Municipal de Investigación Médica (IMIM), Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF), Universitat Autònoma de Barcelona (UAB), Barcelone, Spain. 41Unité de recherche en génétique humaine et moléculaire, Centre de recherche du Centre hospitalier universitaire de Québec - Hôpital St-François-d'Assise (CHUQ/HSFA), Québec City, Canada.  42Department of Public Health and Clinical Medicine, Umeå Unviersity, Umeå, Sweden.  43Musculoskeletal Research Programme, Division of Applied Medicine, University of Aberdeen, Aberdeen, UK.  44Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus C, Denmark.  45MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.  46Ufa Scientific Centre of Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia.  47Biological Department, Bashkir State University, Ufa, Russia.  48Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.  49Department of Genetics and Biotechnology, Faculty of Biology, University of Athens, Athens, Greece.  50Department of Biochemistry and Experimental Medicine, The Children's Memorial Health Institute, Warsaw, Poland.  51Department of Food and Environmental Sciences, University of Helsinki, Helsinki, Finland.  52Jockey Club Centre for Osteoporosis Care and Control, The Chinese University of Hong Kong, Hong Kong SAR, China.  53Department of Internal Medicine, University of Florence, Florence, Italy.  54Department of Clinical Biochemistry, University of Ljubljana, Ljubljana, Slovenia.  55Department of Medical Genetics, University of British Columbia, Vancouver, Canada.  56Department of Endocrinology, University Medical Center, Ljubljana, Slovenia.  57Division of Preventive Medicine, Brigham and Women's Hospital, Boston, USA.  58Department of Medicine, University of Cambridge, Cambridge, UK.  59Department of Surgical and Perioperative Sciences, Umeå Unviersity, Umeå, Sweden.  60Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.  61Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.  62Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University Graz, Graz, Austria.  63Department of Epidemiology and Biostatistics, Extramuraal Geneeskundig Onderzoek (EMGO) Institute for Health and Care Research, Vrije Universiteit (VU) University Medical Center, Amsterdam, The Netherlands.  64Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.  65Department of Genetics, University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelone, Spain.  66Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland.  67Department of Health Sciences, University of Jyväskylä, Jyväskylä, Finland.  68Department of Orthopaedics and Traumatology, Kuopio University Hospital, Kuopio, Finland.  69Center for Clinical and Basic Research (CCBR)-Synarc, Ballerup, Denmark.  70Department of Nutrition and Dietetics, Harokopio University, Athens, Greece.  71Robertson Center for Biostatistics, University of Glasgow, Glasgow, United Kingdom.  72Department of Endocrinology, Odense University Hospital, Odense, Denmark.  73Clinical Institute, University of Southern Denmark, Odense, Denmark.  74Department of Medicine, McGill University, Montreal, Canada.  75Department of Medicine, University of Cantabria, Santander, Spain.  76Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla and Instituto de Formación e Investigación Marqués de Valdecilla (IFIMAV), Santander, Spain.  77Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland.  78Department of Clinical Physiology, University of Tampere School of Medicine, Tampere, Finland.  79Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences and Department of Orthopaedics, Lund University, Malmö, Sweden.  80Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.  81Department of Endocrinology, Vrije Universiteit (VU) University Medical Center, Amsterdam, The Netherlands.  82Extramuraal Geneeskundig Onderzoek (EMGO) Institute for Health and Care Research, Vrije Universiteit (VU) University Medical Center, Amsterdam, The Netherlands.  83Department of Medical Sciences, University of Uppsala, Uppsala, Sweden.  84Department of Pharmacology and Neuroscience, Umeå University, Umeå, Sweden.  85Harvard Medical School, Boston, USA.  86Department of Molecular Biology, Medical Biochemistry and Pathology, Université Laval, Québec City, Canada.  87The APOGEE-Net/CanGèneTest Network on Genetic Health Services and Policy, Université Laval, Québec City, Canada.  88Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.  89Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.  90Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.  91Department of Medical Genetics, University of Antwerp, Antwerp, Belgium.  92Department of Medicine, Turku University Hospital, Turku, Finland.  93Department of Medicine, University of Turku, Turku, Finland.  94Department of Legal Medicine, University of Cantabria, Santander, Spain.  95Department of Human Genetics, McGill University, Montreal, Canada.  96McGill University and Genome Québec Innovation Centre, Montreal, Canada.  97Wellcome Trust Sanger Institute, Hinxton, UK.  98Department of Orthopedic Surgery, Akureyri Hospital, Akureyri, Iceland.  99Institution of Health Science, University Of Akureyri, Akureyri, Iceland.  100Department of Epidemiology and Biostatistics, Lady Davis Institute, McGill University, Montreal, Canada.  101Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.  102Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, USA.  103Department of Endocrinology and Metabolism, University Hospital, Reykjavik, Iceland.  104Genetics of Complex Traits, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, England.  105Department of Clinical Biochemistry, Lovisenberg Deacon Hospital, Oslo, Norway.  106Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.  107Department of Medical Genetics, McGill University Health Centre, Montreal, Canada.  108Division of Genetics and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.  109Program in Medical and Population Genetics, Broad Institute, Cambridge, United States.  110Department of Epidemiology, University of Pittsburgh, Pittsburgh, USA.  111California Pacific Medical Center, San Francisco, CA, USA.  112National Institute for Health and Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Sheffield, Sheffield, UK.  113Department of Internal Medicine, The Ohio State University, Columbus, USA.  114Center for Clinical and Translational Science, The Ohio State University, Columbus, USA.  115Menzies Research Institute, University of Tasmania, Hobart, Australia.  116Durrer Center for Cardiogenetic Research, Amsterdam, The Netherlands.  117Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands.  118Department of Clinical Chemistry, Tampere University Hospital, Tampere, Finland.  119Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere, Finland.  120Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA.  121Academic Unit of Bone Metabolism, Metabolic Bone Centre, University of Sheffield, Sheffield, UK.  122Rural Clinical School, The University of Queensland, Toowoomba, Australia.  123Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.  124Department of Medicine, Indiana University School of Medicine, Indianapolis, USA.  125Department of Medicine, University of Auckland, Auckland, New Zealand.  126Department of Medicine, University of Davis, Sacramento, CA, USA.  127Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia.  128Department of Psychiatry, The University of Hong Kong, Hong Kong, China.  129Centre for Reproduction, Development and Growth, The University of Hong Kong, Hong Kong, China.  130Geriatric Research and Education Clinical Center (GRECC), Veterans Administration Medical Center, Baltimore, MD, USA.  131Department of Preventive Medicine, University of Tennessee College of Medicine, Memphis, TN, USA.  132MRC Epidemiology Unit Box 285, Medical Research Council, Cambridge, UK.  133Framingham Heart Study, Framingham, USA.  134Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, USA.  135Group Health Research Institute, Group Health Cooperative, Seattle, USA.  136Medicine box 157, University of Cambridge, Cambridge, UK.  137Departments of Medicine, Human Genetics, Epidemiology and Biostatistics, Lady Davis Institute, McGill University, Montreal, Canada.  138Stanford Prevention Research Center, Stanford University, Stanford, USA.

139These authors contributed equally to this work.

140These authors jointly directed this work.